author-photo

John H. Eldridge

University of Alabama at Birmingham

147

Papers

7923

Citations

Citation Trend

Filter By

Papers (106) Sort By

Journal Conference Others

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses.

2021 Vaccine
Show All
- Source
- Cite
- Save
Citations (0)
Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial

2020 Lancet Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (12)
Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates

2018 The Journal of Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (10)
Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers

2018 Molecular Therapy - Oncolytics
Show All
- Source
- Cite
- Save
Citations (5)
DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA.

2017 Clinical and Vaccine Immunology
Show All
- Source
- Cite
- Save
Citations (23)
A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection

2017 Science Translational Medicine
Show All
- Source
- Cite
- Save
Citations (73)
G-111 DNA prime/subunit boost using SIVE660 based rhFLSC yields 75% efficacy against cross clade SIVmac251 intrarectal challenge:

2016 Journal of Acquired Immune Deficiency Syndromes
Show All
- Source
- Cite
- Save
Citations (0)
The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection.

2016 Journal of Acquired Immune Deficiency Syndromes
Show All
- Source
- Cite
- Save
Citations (20)
First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).

2015 Open Forum Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (46)
Vaccination with a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge with a Lethal Dose of Ebola Virus

2015 The Journal of Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (35)